Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alice Y Zhou, M.D., Ph.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University School of Medicine
St Louis, Missouri, United States
Alice Y Zhou, M.D., Ph.D.Amanda Cashen, M.D.Armin Ghobadi, M.D.Charles Kaufman, M.D., Ph.D.Feng Gao, M.D., Ph.D., MPH, MSGeorge Ansstas, M.D.Jesse Keller, M.D.Ryan Fields, M.D.Tanner M Johanns, M.D., Ph.D.Todd A Fehniger, M.D., Ph.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Nov 2024
- Primary completion
- 28 Feb 2029
- Completion
- 30 Nov 2030
- Last update posted
- 12 Sept 2025
- Registered enrollment
- 33
- Registry id
- NCT05629546
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.